

Markolf Hanefeld

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1111857/markolf-hanefeld-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

55
papers

7,138
citations

26
h-index

59
g-index

59
ext. papers

7,877
ext. citations

9.3
avg, IF

5.35
L-index

#	Paper	IF	Citations
55	Treatment: Alpha Glucosidase Inhibitors 2019 , 238-244		1
54	Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol. <i>Diabetes Therapy</i> , 2018 , 9, 37-47	3.6	2
53	A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1645-1654	6.7	21
52	Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1594-1601	6.7	12
51	The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100U/mL. <i>Cardiovascular Diabetology</i> , 2017 , 16, 66	8.7	9
50	Intra-individual variability and circadian rhythm of vascular endothelial growth factors in subjects with normal glucose tolerance and type 2 diabetes. <i>PLoS ONE</i> , 2017 , 12, e0184234	3.7	7
49	Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 311-321	5.5	3
48	Hypoglycemia and Cardiovascular Risk: Is There a Major Link?. <i>Diabetes Care</i> , 2016 , 39 Suppl 2, S205-9	14.6	73
47	Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial. <i>Diabetes Care</i> , 2016 , 39, 1318-28	14.6	103
46	The metabolic vascular syndrome - guide to an individualized treatment. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2016 , 17, 5-17	10.5	25
45	Metabolic Vascular Syndrome: New Insights into a Multidimensional Network of Risk Factors and Diseases. <i>Visceral Medicine</i> , 2016 , 32, 319-326	2.4	9
44	Risk of and risk factors for hypoglycemia and associated arrhythmias in patients with type 2 diabetes and cardiovascular disease: a cohort study under real-world conditions. <i>Acta Diabetologica</i> , 2015 , 52, 889-95	3.9	53
43	Clinical features and treatment of coronary heart disease in diabetes 2015 , 1064-1078		1
42	Hypoglycemia and Cardiovascular Disease: Lessons from Outcome Studies. <i>Current Diabetes Reports</i> , 2015 , 15, 117	5.6	8
41	Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials. <i>Advances in Therapy</i> , 2014 , 31, 861-72	4.1	14
40	Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). <i>Journal of Diabetes and Its Complications</i> , 2014 , 28, 386-92	3.2	90
39	Differences in Glycemic Variability Between Normoglycemic and Prediabetic Subjects. <i>Journal of Diabetes Science and Technology</i> , 2014 , 8, 286-290	4.1	24

38	Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias. <i>Diabetes Care</i> , 2014 , 37, 516-20	14.6	111
37	Insulin use early in the course of type 2 diabetes mellitus: the ORIGIN trial. <i>Current Diabetes Reports</i> , 2013 , 13, 342-9	5.6	17
36	Cardiac implications of hypoglycaemia in patients with diabetes - a systematic review. <i>Cardiovascular Diabetology</i> , 2013 , 12, 135	8.7	56
35	Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies. <i>Diabetes and Vascular Disease Research</i> , 2013 , 10, 302-14	3.3	63
34	The Metabolic Syndrome and Cardiovascular Disease 2013 , 43-54		1
33	Decreasing Postprandial Plasma Glucose Using an α -Glucosidase Inhibitor in Subjects with IGT for the Prevention of Type 2 Diabetes Mellitus: The STOP-NIDDM Trial 2012 , 167-187		1
32	Acarbose revisited for efficacy, safety and cardiovascular benefits: a key role for controlling glycemic variability. <i>Expert Review of Endocrinology and Metabolism</i> , 2012 , 7, 395-405	4.1	1
31	Conversion of IGT to type 2 diabetes mellitus is associated with incident cases of hypertension: a post-hoc analysis of the STOP-NIDDM trial. <i>Journal of Hypertension</i> , 2012 , 30, 1440-3	1.9	14
30	Drug therapy for the prevention of type 2 diabetes ¶s there a medical rationale?. <i>British Journal of Diabetes and Vascular Disease</i> , 2011 , 11, 168-174		1
29	Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PICOOMB study. <i>Cardiovascular Diabetology</i> , 2011 , 10, 65	8.7	31
28	Is hyperglycemia a cardiovascular risk factor?. <i>Diabetes Care</i> , 2011 , 34 Suppl 2, S128-31	14.6	43
27	Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study. <i>Journal of Diabetes Science and Technology</i> , 2011 , 5, 989-98	4.1	5
26	Review of approved pioglitazone combinations for type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 1571-84	4	9
25	High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone. <i>Journal of Diabetes Science and Technology</i> , 2010 , 4, 706-16	4.1	55
24	Dapagliflozin, an SGLT2 inhibitor, for diabetes. <i>Lancet, The</i> , 2010 , 375, 2196-8	40	21
23	Shifting the disease management paradigm from glucose: what are the cons?. <i>Diabetes Care</i> , 2009 , 32 Suppl 2, S353-6	14.6	
22	Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial. <i>Diabetes and Vascular Disease Research</i> , 2009 , 6, 32-7	3.3	21
21	The "glucose pentagon": assessing glycemic control of patients with diabetes mellitus by a model integrating different parameters from glucose profiles. <i>Diabetes Technology and Therapeutics</i> , 2009 , 11, 399-409	8.1	25

20	Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. <i>Lancet, The</i> , 2009 , 373, 2125-35	4.0	1059
19	Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study. <i>Atherosclerosis</i> , 2008 , 201, 155-62	3.1	12
18	Acarbose: oral anti-diabetes drug with additional cardiovascular benefits. <i>Expert Review of Cardiovascular Therapy</i> , 2008 , 6, 153-63	2.5	57
17	Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk. <i>Diabetes and Vascular Disease Research</i> , 2008 , 5, 298-303	3.3	37
16	Effect of acarbose on vascular disease in patients with abnormal glucose tolerance. <i>Cardiovascular Drugs and Therapy</i> , 2008 , 22, 225-31	3.9	29
15	Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 290-7	15.1	141
14	Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study. <i>Cardiovascular Diabetology</i> , 2007 , 6, 13	8.7	46
13	Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2007 , 6, 20	8.7	62
12	Is rosiglitazone associated with increased risk for cardiovascular events?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007 , 4, 648-9		2
11	Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. <i>New England Journal of Medicine</i> , 2007 , 357, 28-38	59.2	618
10	A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007 , 17, 13-23	4.5	29
9	Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006 , 16, 453-6	4.5	109
8	In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. <i>Diabetes Care</i> , 2004 , 27, 484-90	14.6	198
7	Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. <i>Stroke</i> , 2004 , 35, 1073-8	6.7	230
6	Postprandial glucose regulation and diabetic complications. <i>Archives of Internal Medicine</i> , 2004 , 164, 2090-5		251
5	Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. <i>JAMA - Journal of the American Medical Association</i> , 2003 , 290, 486-94	27.4	1200
4	Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. <i>Lancet, The</i> , 2002 , 359, 2072-7	4.0	1933
3	Restoring early-phase insulin secretion [the new goal in type 2 diabetes management. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2001 , 18, S10-S12		1

- | | | | |
|---|---|------|-----|
| 2 | Stable isotope ratio analysis of amino acids: the use of N(O,S)-ethoxycarbonyl trifluoroethyl ester derivatives and gas chromatography/mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 1997 , 11, 1835-8 | 2.2 | 11 |
| 1 | Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. <i>Diabetes Care</i> , 1991 , 14, 732-7 | 14.6 | 176 |